Screener
Eligibility screening
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Study detailsClinicalTrials.gov
2 US sites in TX, UT
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.